é^´æœ¨ æ²å¾

List of Publications by Year
in descending order

Version: 2024-02-01

142 papers	5,117 citations	279798 23 h-index	95266 68 g-index
154 all docs	154 docs citations	154 times ranked	4294 citing authors

#	Article	IF	Citations
1	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 1319-1331.	27.0	1,210
2	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine, 2018, 378, 518-528.	27.0	747
3	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2018, 379, 1811-1822.	27.0	413
4	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 395, 132-141.	13.7	299
5	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	27.0	268
6	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1630-1642.	10.7	237
7	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
8	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet, The, 2021, 397, 2361-2371.	13.7	177
9	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e448-e458.	4.6	168
10	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia, 2019, 33, 1687-1699.	7.2	98
11	Clinical profiles of multiple myeloma in Asiaâ€”An Asian Myeloma Network study. American Journal of Hematology, 2014, 89, 751-756.	4.1	88
12	A multicenter, openâ€label, phase II study of tirabrutinib (ONO/GSâ€4059) in patients with WaldenstrÃ¶mâ€™s macroglobulinemia. Cancer Science, 2020, 111, 3327-3337.	3.9	60
13	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood, 2021, 137, 3616-3628.	1.4	48
14	Elevated Serum Interleukin-6 in POEMS Syndrome Reflects the Activity of the Disease.. Internal Medicine, 1994, 33, 583-587.	0.7	46
15	Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an openâ€label Phase II study. British Journal of Haematology, 2021, 192, 869-878.	2.5	43
16	Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 1888-1888.	1.4	35
17	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139.	1.4	34
18	Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer Journal, 2018, 8, 41.	6.2	32

#	Article	IF	Citations
19	Current Therapeutic Strategy for Multiple Myeloma. Japanese Journal of Clinical Oncology, 2013, 43, 116-124.	1.3	31
20	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	7.2	29
21	Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. International Journal of Hematology, 2015, 101, 286-294.	1.6	28
22	Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis. International Journal of Hematology, 2017, 105, 295-308.	1.6	26
23	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. Blood, 2019, 134, 142-142.	1.4	25
24	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 785-798.	0.4	22
25	Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8509-8509.	1.6	22
26	Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clinical and Experimental Nephrology, 2012, 16, 659-671.	1.6	21
27	Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. International Journal of Hematology, 2016, 103, 53-62.	1.6	21
28	Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. European Journal of Clinical Pharmacology, 2016, 72, 153-161.	1.9	21
29	Amelioration of NK cell function driven by Vî±24 + invariant NKT cell activation in multiple myeloma. Clinical Immunology, 2018, 187, 76-84.	3.2	20
30	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. Blood, 2018, 132, 156-156.	1.4	20
31	Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma. Molecular Therapy - Oncolytics, 2017, 6, 57-68.	4.4	19
32	A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. British Journal of Haematology, 2016, 172, 745-756.	2.5	18
33	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leukemia and Lymphoma, 2018, 59, 2305-2317.	1.3	18
34	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone. Blood, 2019, 134, 859-859.	1.4	18
35	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. Journal of Clinical Oncology, 2017, 35, 8006-8006.	1.6	18
36	A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.. Journal of Clinical Oncology, 2018, 36, 8010-8010.	1.6	18

#	Article	IF	Citations
37	Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. Cancer Science, 2017, 108, 461-468.	3.9	16
38	Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. International Journal of Hematology, 2018, 107, 173-184.	1.6	15
39	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Blood, 2020, 136, 7-8.	1.4	15
40	Twoâ€year outcomes of tirabrutinib monotherapy in WaldenstrÃ¶mâ€™s macroglobulinemia. Cancer Science, 2022, 113, 2085-2096.	3.9	15
41	Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. International Journal of Hematology, 2017, 106, 562-572.	1.6	14
42	A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Experimental Hematology and Oncology, 2015, 5, 11.	5.0	13
43	Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. International Journal of Hematology, 2017, 105, 445-452.	1.6	13
44	Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. International Journal of Hematology, 2017, 106, 541-551.	1.6	13
45	A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. Internal Medicine, 2018, 57, 939-946.	0.7	13
46	Healthâ€related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. British Journal of Haematology, 2021, 194, 132-139.	2.5	13
47	Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-NaÃ¯ve or Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia. Blood, 2019, 134, 345-345.	1.4	13
48	Lenalidomide and lowâ€dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase <scp>II</scp> study. Cancer Science, 2016, 107, 653-658.	3.9	12
49	Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. International Journal of Hematology, 2017, 105, 470-477.	1.6	12
50	Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database. Journal of Medical Economics, 2020, 23, 166-173.	2.1	12
51	Exposureâ€Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. Journal of Clinical Pharmacology, 2021, 61, 614-627.	2.0	12
52	Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE). Blood, 2017, 130, LBA-4-LBA-4.	1.4	12
53	A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.. Blood, 2012, 120, 2954-2954.	1.4	12
54	The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 1392-1398.	2.0	11

#	Article	IF	Citations
55	A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination. Leukemia, 2019, 33, 1773-1782.	7.2	11
56	Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Annals of Hematology, 2019, 98, 1703-1711.	1.8	11
57	Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. International Journal of Hematology, 2020, 111, 65-74.	1.6	11
58	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. Blood, 2020, 136, 48-50.	1.4	11
59	Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology, 2018, 107, 460-467.	1.6	10
60	Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Science, 2020, 111, 4526-4539.	3.9	10
61	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. Blood, 2018, 132, 3288-3288.	1.4	10
62	High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. International Journal of Hematology, 2016, 103, 299-305.	1.6	9
63	Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. International Journal of Hematology, 2020, 111, 692-701.	1.6	9
64	Poor mobilizer and its countermeasures. Transfusion and Apheresis Science, 2018, 57, 623-627.	1.0	8
65	Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Annals of Hematology, 2019, 98, 2805-2814.	1.8	8
66	Expression of activated integrin Î²7 in multiple myeloma patients. International Journal of Hematology, 2021, 114, 3-7.	1.6	8
67	Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer, 2021, 21, 659.	2.6	8
68	Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 221-224.	3.0	7
69	Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis. International Journal of Hematology, 2016, 103, 79-85.	1.6	7
70	Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. Cancer Science, 2019, 110, 2924-2932.	3.9	7
71	The efficacy and safety of modified bortezomibâ€lenalidomideâ€dexamethasone in transplantâ€eligible patients with newly diagnosed multiple myeloma. European Journal of Haematology, 2020, 104, 110-115.	2.2	7
72	Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. International Journal of Hematology, 2020, 111, 512-518.	1.6	7

#	Article	IF	Citations
73	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. British Journal of Haematology, 2021, 194, 784-788.	2.5	7
74	Ixazomib-dexamethasone (Ixa-Dex) vs physicianâ€™s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology, 2020, 38, 8546-8546.	1.6	7
75	Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia, 2020, 34, 3088-3090.	7.2	7
76	Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2020, 136, 10-11.	1.4	6
77	MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry. Blood, 2019, 134, 1832-1832.	1.4	6
78	CD56 for Multiple Myeloma: Lack of CD56 May Be Associated with Worse Prognosis. Acta Haematologica, 2018, 140, 40-41.	1.4	4
79	Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis. International Journal of Hematology, 2019, 110, 431-437.	1.6	4
80	Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis. International Journal of Hematology, 2020, 111, 103-111.	1.6	4
81	Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update. Blood, 2019, 134, 3152-3152.	1.4	4
82	Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).. Journal of Clinical Oncology, 2017, 35, 8025-8025.	1.6	4
83	Pomalidomideâ€bortezomibâ€dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. Cancer Science, 2020, 111, 2116-2122.	3.9	4
84	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Advances, 2022, 6, 4506-4515.	5.2	4
85	Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.. Journal of Clinical Oncology, 2022, 40, 8052-8052.	1.6	4
86	Severe thrombocytopenia after cytomegalovirus infection in an immunocompetent host. Correlation between CMV infection and platelet count in immunocompetent hosts.. Japanese Journal of Clinical Immunology, 1997, 20, 134-138.	0.0	3
87	Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 191-203.	2.5	3
88	Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Annals of Hematology, 2021, 100, 2989-2995.	1.8	3
89	Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. International Journal of Hematology, 2021, 114, 653-663.	1.6	3
90	Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study. Blood, 2018, 132, 3260-3260.	1.4	3

#	Article	IF	Citations
91	Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts. Blood, 2020, 136, 28-30.	1.4	3
92	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. Blood, 2020, 136, 11-11.	1.4	3
93	Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria. International Journal of Hematology, 2017, 105, 231-232.	1.6	2
94	Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 293-296.	0.4	2
95	Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma. Hematological Oncology, 2018, 36, 363-365.	1.7	2
96	Autologous Hematopoietic Cell Transplantation Versus Chemotherapy Alone for Immunoglobulin Light Chain Amyloidosis: A Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 413-422.e5.	0.4	2
97	Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. International Journal of Hematology, 2020, 111, 57-64.	1.6	2
98	Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients. International Journal of Hematology, 2020, 112, 640-649.	1.6	2
99	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. Leukemia and Lymphoma, 2020, 61, 1688-1694.	1.3	2
100	Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. Acta Haematologica, 2021, 144, 264-274.	1.4	2
101	Sustained Molecular Response with Maintenance Dose of Interferon Alfa After Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia. Blood, 2012, 120, 1684-1684.	1.4	2
102	Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomideâ€“Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2014, 124, 5752-5752.	1.4	2
103	The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients. Blood, 2016, 128, 4529-4529.	1.4	2
104	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. Journal of Clinical Oncology, 2018, 36, e20024-e20024.	1.6	2
105	Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. PLoS ONE, 2015, 10, e0128662.	2.5	2
106	Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-NaÃ¯ve or Relapsed/Refractory WaldenstrÃ¶m's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-NaÃ¯ve or Relapsed/Refractory WaldenstrÃ¶m's Macroglobulinemia. Blood, 2021, 138, 1352-1352.	1.4	2
107	Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. International Journal of Hematology, 2022, 116, 553-562.	1.6	2
108	Coexistent adrenal diffuse large B cell lymphoma in a patient with WaldenstrÃ¶mâ€™s macrogloblinemia/lymphoplasmacytic lymphoma. Annals of Hematology, 2016, 95, 1723-1724.	1.8	1

#	Article	IF	Citations
109	Elevation of Plasmin-Î±2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis. Internal Medicine, 2018, 57, 775-776.	0.7	1
110	Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation. International Journal of Hematology, 2019, 110, 447-457.	1.6	1
111	Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR. International Journal of Hematology, 2021, 113, 219-230.	1.6	1
112	Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients. International Journal of Hematology, 2021, 113, 777-784.	1.6	1
113	Identification of clonal immunoglobulin Î» light-chain gene rearrangements in AL amyloidosis using next-generation sequencing. Experimental Hematology, 2021, 101-102, 34-41.e4.	0.4	1
114	Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder. Blood, 2011, 118, 2871-2871.	1.4	1
115	Difference of Treatment Outcomes in AL Amyloidosis and Multiple Myeloma with / without Translocation (11;14). Blood, 2015, 126, 4224-4224.	1.4	1
116	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. Journal of Clinical Oncology, 2012, 30, 8097-8097.	1.6	1
117	Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.. Journal of Clinical Oncology, 2020, 38, 8547-8547.	1.6	1
118	Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan. Blood, 2012, 120, 1816-1816.	1.4	1
119	DISTRIBUTION OF IMMUNOGLOBULIN CONTAINING CELLS IN HUMAN BONE MARROW OF PATIENTS WITH LEUKEMIA. Pathology International, 1987, 37, 193-199.	1.3	0
120	Isatuximab plus carfilzomib and dexamethasone in east Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, e20015-e20015.	1.6	0
121	Adoptive Immunotherapy Using Zoledronate-Activated gd T LAK Cells to Patients with Multiple Myeloma: A Pilot Study.. Blood, 2006, 108, 5096-5096.	1.4	0
122	Sucessful Management of Pregnancy and Remission-Induction of a Patient with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) by Means of Imatinib Mesilate and HyperCVAD.. Blood, 2007, 110, 4327-4327.	1.4	0
123	A Phase I/II Study of Bortezomib in Combination with Melphalan and Prednisolone in Japanese Patients with Newly Diagnosed Multiple Myeloma. Blood, 2011, 118, 5132-5132.	1.4	0
124	Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65â€“70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network. Blood, 2012, 120, 5030-5030.	1.4	0
125	Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study. Blood, 2012, 120, 5035-5035.	1.4	0
126	Discovery Research On the Effects of Continuous Administration of Bortezomib Maintenance Therapy to Treat Patients with Relapsed and Refractory Multiple Myeloma - Analysis of Background Factors That Affect the Continuity of Therapy-. Blood, 2012, 120, 1866-1866.	1.4	0

#	Article	IF	Citations
127	Impact Of Novel Agents To The Additional-Chromosomal Abnormalities In Patients With Multiple Myeloma. Blood, 2013, 122, 3225-3225.	1.4	0
128	Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients. Blood, 2014, 124, 3452-3452.	1.4	0
129	Therapy-Free Remission after Interferon Alfa Maintenance with Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia. Blood, 2014, 124, 5519-5519.	1.4	0
130	Survival of Multiple Myeloma Patients in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma. Blood, 2014, 124, 5684-5684.	1.4	0
131	A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma. Blood, 2015, 126, 4199-4199.	1.4	0
132	MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan. Blood, 2015, 126, 5374-5374.	1.4	0
133	Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial. Blood, 2016, 128, 3315-3315.	1.4	0
134	A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma. Blood, 2016, 128, 4436-4436.	1.4	0
135	Survival of Patients with Multiple Myeloma That Is Refractory to Both Bortezomib and Lenalidomide: A Retrospective Study. Blood, 2018, 132, 2020-2020.	1.4	0
136	Retrospective Analysis of the Efficacy and Safety of Modified Bortezomib-Lenalidomide-Dexamethasonelite (modified RVD-lite) Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1961-1961.	1.4	0
137	Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma. Blood, 2019, 134, 3085-3085.	1.4	0
138	Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone. Blood, 2019, 134, 3177-3177.	1.4	0
139	Identification of Clonal Immunoglobulin Î» Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing. Blood, 2019, 134, 1748-1748.	1.4	0
140	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. Blood, 2021, 138, 4771-4771.	1.4	0
141	Prospective Comparison Study of Prognostic Value of MRD Detected By 8-Color MFC (EuroFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting. Blood, 2021, 138, 3946-3946.	1.4	0
142	The Clinical Features of Multiple Myeloma with AL Amyloidosis. Blood, 2020, 136, 10-10.	1.4	0